Navigation Links
Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Date:12/9/2010

EAST HANOVER, N.J., Dec. 9, 2010 /PRNewswire/ -- A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas(1).  

Findings from a randomized, Phase II study of 111 patients showed the proportion of metastatic breast cancer patients without tumor progression at six months was 61.1% for those taking everolimus plus tamoxifen (95% confidence interval [CI], 46.9 to 74.1) versus 42.1% for patients treated with tamoxifen alone (95% CI, 29.1 to 55.9); p=0.045(1).  

Disease progression was delayed by a median of 8.6 months in patients treated with the combination versus 4.5 months in patients treated with tamoxifen alone, with everolimus in combination with tamoxifen providing a statistically significant reduction in the risk of disease progression by 47% (hazard ratio=0.53 [95% CI, 0.35 to 0.81]; log-rank test: p=0.0026, exploratory analysis). Side effects were generally manageable in both study arms. As of October 2010, there were 25 patient deaths in the tamoxifen arm versus nine in the everolimus plus tamoxifen arm (hazard ratio=0.32 [95% CI, 0.15 to 0.68]; log-rank test: p=0.0019)(1).

This Phase II trial is conducted by the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (the French GINECO Group).

Everolimus is an investigational agent for the treatment of patients with breast cancer. Everolimus targets mTOR in cancer cells, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism(7,8).

"The almost doubling of time to di
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015  IRIDEX Corporation (NASDAQ: IRIX ... and full year 2014 financial results after the market closes ... the release, the Company will host a conference call with ... Thursday, March 5, 2015 to discuss the ... Interested parties may access the live conference call via telephone ...
(Date:2/26/2015)... WASHINGTON , Feb. 26, 2015  Mail-service ... consumers, employers and government health plans ... research released by the Pharmaceutical Care Management Association ... specialty drugs offers one of the easiest ways ... CEO Mark Merritt . "Policymakers should resist ...
(Date:2/26/2015)... , Feb. 26, 2015 Every year many ... to fight heart disease.  Nevertheless, year after year doctors ... (EKG) as the first test to determine the status ... chest pain or not, even though that technology is ... the fact that doctors know, (while most patients do ...
Breaking Medicine Technology:IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2National Heart Health Month In February 2
... N.C. , July 21 /PRNewswire-FirstCall / -- SPX ... completed the acquisition of the Anhydro business, a Soeborg, Denmark ... dewatering plants and equipment.  The terms of the transaction were not ... Anhydro ...
... DETROIT , July 21 Caraco Pharmaceutical ... shipping bupropion hydrochloride extended release tablets. This product was ... (FDA) for Sun Pharma,s Abbreviated New Drug Application (ANDA). ... mg, and 200 mg, are therapeutically equivalent to GlaxoSmithKline,s ...
Cached Medicine Technology:SPX Completes Acquisition of Anhydro 2SPX Completes Acquisition of Anhydro 3Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Wellbutrin SR® Extended Release Tablets 2
(Date:2/28/2015)... The noted Friedman Dental Group of South ... relaunched their website. The new version of the site ... new section about their team members. Potential and current ... of each Friedman Dental Group team member including new ... to provide our patients with the opportunity to get ...
(Date:2/28/2015)... 2015 Developers of FCPX plugins ... overlay plugin for Final Cut Pro X entitled FCPX Overlay ... Chromatic gives users total control over 6k lens dirt overlays ... Pixel Film Studios. “FCPX Overlay Chromatic was professionally designed to ... interface.” , FCPX Overlay Chromatic Grunge 6K is a resourceful ...
(Date:2/28/2015)... “ Powermod ” was featured on NewsWatch as ... at the latest and coolest technology products and services available ... a technology expert, conducted the review and shared with viewers ... Getting stuck with a low battery and no way to ... face on a daily basis. Even when a person does ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Memphis, TN: ... 5, 2015, for a new security reader named ... The reader is a new biometric scanner that ... with new features, the new biometric scanner provides ... and administrators. , MedixSafe narcotics lockers ...
(Date:2/28/2015)... Las Vegas, NV (PRWEB) February 28, 2015 ... products, will be sending a team to Las Vegas, Nevada ... ASD Market Week is one of the leading consumer-goods tradeshows ... 2,600 vendors at this year’s event. My Shiney Hiney can ... delivers a fresh, modern design for the at-home personal hygiene ...
Breaking Medicine News(10 mins):Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2
... dyes, researchers have shown that they can identify tumors ... may allow doctors to detect and diagnose cancer earlier ... ScFv peptides that bind cancer cells, the gold particles ... When illuminated with a laser beam, the tumor-bound particles ...
... GLENDALE, Calif., Dec. 23 The California,Nurses ... condolences to the family of Nataline Sarkysian, and ... liver transplant one week,earlier for the 17-year-old, who ... to the procedure following a massive national outcry.,CNA/NNOC ...
... Mylan Inc. (NYSE: MYL ),today announced that due ... 31 to December 31, it is scheduling its next annual ... 25, 2008, as the date of,its 2008 Annual Meeting of ... the Company matters to be brought before the annual,meeting (except ...
... for December 26, 2007 at 5:00 pm ET, ... (Nasdaq: ENSG ), the parent company of the ... living,companies, today timely filed its Form 10-Q and reported ... 2007. The,Company,s third quarter 2007 financial results were consistent ...
... about $555, government analysis shows., , , FRIDAY, Dec. 21 ... cancer for under- or uninsured low-income U.S. women cost ... new government analysis. , The total cost per woman ... is about $555, according to the analysis of the ...
... TAXUS Liberte has more CE Mark-approved indications than any other ... ... Boston Scientific,Corporation (NYSE: BSX ) announced today that its TAXUS(R) ... in patients with diabetes.(1) Boston Scientific submitted,data showing the TAXUS Liberte ...
Cached Medicine News:Health News:Gold nanoparticle probes may allow earlier cancer detection 2Health News:Gold nanoparticle probes may allow earlier cancer detection 3Health News:Nataline Sarkysian Vigil Sunday 2Health News:The Ensign Group, Inc. Reports Third Quarter 2007 Earnings 2Health News:The Ensign Group, Inc. Reports Third Quarter 2007 Earnings 3Health News:The Ensign Group, Inc. Reports Third Quarter 2007 Earnings 4Health News:The Ensign Group, Inc. Reports Third Quarter 2007 Earnings 5Health News:The Ensign Group, Inc. Reports Third Quarter 2007 Earnings 6Health News:The Ensign Group, Inc. Reports Third Quarter 2007 Earnings 7Health News:The Ensign Group, Inc. Reports Third Quarter 2007 Earnings 8Health News:The Ensign Group, Inc. Reports Third Quarter 2007 Earnings 9Health News:Low-Income Women's Cancer Screenings Cost Effective: Report 2Health News:Low-Income Women's Cancer Screenings Cost Effective: Report 3Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 2Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 3Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 4Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 5
... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... developed a range of Milli-Q ultrapure ... water quality requirements. Each of the ... to specifically target contaminants detrimental to ... biology and ICP-MS. The systems incorporate ...
Medicine Products: